Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Consensus Target Price of $12.67 According to Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been assigned a consensus recommendation of “Hold” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $12.67.

VRCA has been the topic of several recent analyst reports. Lake Street Capital initiated coverage on Verrica Pharmaceuticals in a research note on Thursday, August 27th. They set a “buy” rating and a $9.00 price objective on the stock. Wall Street Zen upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, October 13th.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Renaissance Technologies LLC boosted its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 32,360 shares of the company’s stock after purchasing an additional 5,960 shares during the period. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Trading Down 4.2%

Shares of Verrica Pharmaceuticals stock opened at $3.21 on Tuesday. The stock has a fifty day simple moving average of $4.37 and a 200 day simple moving average of $5.60. Verrica Pharmaceuticals has a 12-month low of $3.20 and a 12-month high of $9.82. The company has a market capitalization of $55.15 million, a P/E ratio of -1.92 and a beta of 1.60. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.